English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Objective: Multiple myeloma (MM) is a malignant disease which develops due to the proliferation of only one clonal plasma cell. Treatment response can influence the long term results of the disease and assessing this response as early as possible is important in determining treatment strategies. The purpose of this study was to find out whether the decrease in immunoglobulins, following a cycle of chemotheraphy could predict the rate of treatment response, progression free survival (PFS) and overal survival (OS). Patients and Methods: One hundred and fifty-three MM patients who had been newly diagnosed our clinic between January 2007-February 2016 and who had been followed up in our center were evaluated retrospectively. The patients treatments, treatment responses, survival and progression-free survival times were found. The difference between immunoglobulin levels at the time of diagnosis and immunoglobulin levels at the end of first cycle was found. These rates were compared with treatment response, PFS and OS. Elif AKYAZI1, Engin KELKİTLİ2, Mehmet TURGUT2 1 Sağlık Bilimleri Üniversitesi Samsun Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, Samsun, Türkiye 2 Ondokuz Mayıs Üniversitesi Tıp Fakültesi, Hematoloji Bilim Dalı, Samsun, Türkiye Doç. Dr. Engin KELKİTLİ Ondokuz Mayıs Üniversitesi Tıp Fakültesi, Hematoloji Bilim Dalı, Samsun-Türkiye Geliş: 10.06.2019 Kabul: 17.07.2019 E-posta: ekelkitli@gmail.com Yazışma Adresi ARAŞTIRMA LLM Dergi 2019;3(2):38-44 • 10.5578/llm.68518 Makale atıfı: Akyazı E, Kelkitli E, Turgut M. Yeni tanı multipl miyelom hastalarında ilk kür tedavi sonrası immünoglobulin düzeyindeki azalma önemli mi? LLM Dergi 2019;3(2):38-44.

Is the Decrease in the Immunoglobulin Level Important After First Cycle Chemotheraphy of the Newly Diagnosed Multiple Myeloma Patients?